Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Non-Current Liabilities: 2017-2023

Historic Total Non-Current Liabilities for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to $118.1 million.

  • Denali Therapeutics' Total Non-Current Liabilities fell 71.61% to $118.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $118.1 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of $417.4 million for FY2022, which is 5.45% down from last year.
  • Denali Therapeutics' Total Non-Current Liabilities amounted to $118.1 million in Q3 2023, which was down 0.39% from $118.5 million recorded in Q2 2023.
  • Denali Therapeutics' 5-year Total Non-Current Liabilities high stood at $453.0 million for Q4 2020, and its period low was $118.1 million during Q3 2023.
  • In the last 3 years, Denali Therapeutics' Total Non-Current Liabilities had a median value of $417.4 million in 2022 and averaged $370.8 million.
  • In the last 5 years, Denali Therapeutics' Total Non-Current Liabilities skyrocketed by 201.41% in 2021 and then slumped by 71.61% in 2023.
  • Over the past 5 years, Denali Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $158.0 million in 2019, then soared by 186.81% to $453.0 million in 2020, then decreased by 2.55% to $441.5 million in 2021, then declined by 5.45% to $417.4 million in 2022, then tumbled by 71.61% to $118.1 million in 2023.
  • Its Total Non-Current Liabilities stands at $118.1 million for Q3 2023, versus $118.5 million for Q2 2023 and $442.3 million for Q1 2023.